Home › Compare › AGLE vs VICI

AGLE vs VICI: Dividend Comparison 2026

AGLE yields 16.65% · VICI yields 6.52%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VICI wins by $906.9K in total portfolio value· pulled ahead in Year 5
10 years
AGLE
AGLE
● Live price
16.65%
Share price
$12.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$59.3K
Annual income
$4,631.17
Full AGLE calculator →
VICI
VICI Properties Inc.
● Live price
6.52%
Share price
$27.32
Annual div
$1.78
5Y div CAGR
44.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$966.2K
Annual income
$607,376.13
Full VICI calculator →

Portfolio growth — AGLE vs VICI

📍 VICI pulled ahead of the other in Year 5

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAGLEVICI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AGLE + VICI cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
AGLE pays
VICI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AGLE
Annual income on $10K today (after 15% tax)
$1,415.49/yr
After 10yr DRIP, annual income (after tax)
$3,936.49/yr
VICI
Annual income on $10K today (after 15% tax)
$554.58/yr
After 10yr DRIP, annual income (after tax)
$516,269.71/yr
At 15% tax rate, VICI beats the other by $512,333.22/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AGLE + VICI for your $10,000?

AGLE: 50%VICI: 50%
100% VICI50/50100% AGLE
Portfolio after 10yr
$512.8K
Annual income
$306,003.65/yr
Blended yield
59.67%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on VICI right now

AGLE
Analyst Ratings
3
Buy
5
Hold
Consensus: Hold
Altman Z
-1.2
Piotroski
3/9
VICI
Analyst Ratings
20
Buy
6
Hold
Consensus: Buy
Price Target
$31.60
+15.7% upside vs current
Range: $30.00 — $33.00
Altman Z
1.4
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AGLE buys
0
VICI buys
0
No recent congressional trades found for AGLE or VICI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAGLEVICI
Forward yield16.65% ✓6.52%
Annual dividend / share$2.00 ✓$1.78
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%44.3% ✓
Portfolio after 10y$59.3K$966.2K ✓
Annual income after 10y$4,631.17$607,376.13 ✓
Total dividends collected$30.5K$926.2K ✓
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldBuy

Year-by-year: AGLE vs VICI ($10,000, DRIP)

YearAGLE PortfolioAGLE Income/yrVICI PortfolioVICI Income/yrGap
1$12,365$1,665.28$11,361$941.49+$1.0K → AGLE
2$15,155$1,924.45$13,320$1,481.32+$1.8K → AGLE
3$18,421$2,204.37$16,284$2,405.01+$2.1K → AGLE
4$22,214$2,504.02$21,040$4,071.78+$1.2K → AGLE
5← crossover$26,591$2,822.14$29,209$7,285.49$2.6K → VICI
6$31,610$3,157.22$44,443$14,006.51$12.8K → VICI
7$37,330$3,507.56$75,822$29,512.55$38.5K → VICI
8$43,814$3,871.31$148,733$69,726.75$104.9K → VICI
9$51,128$4,246.52$344,394$189,413.75$293.3K → VICI
10$59,338$4,631.17$966,234$607,376.13$906.9K → VICI

AGLE vs VICI: Complete Analysis 2026

AGLE — Stock

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

Full AGLE Calculator →

VICI — REIT

VICI Properties is an experiential real estate investment trust that owns one of the largest portfolios of market-leading gaming, hospitality and entertainment destinations, including the world-renowned Caesars Palace. VICI Properties' national, geographically diverse portfolio consists of 29 gaming facilities comprising over 48 million square feet and features approximately 19,200 hotel rooms and more than 200 restaurants, bars and nightclubs. Its properties are leased to industry leading gaming and hospitality operators, including Caesars Entertainment, Inc., Century Casinos Inc., Hard Rock International, JACK Entertainment and Penn National Gaming, Inc. VICI Properties also owns four championship golf courses and 34 acres of undeveloped land adjacent to the Las Vegas Strip. VICI Properties' strategy is to create the nation's highest quality and most productive experiential real estate portfolio.

Full VICI Calculator →
📬

Get this AGLE vs VICI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AGLE vs SCHDAGLE vs JEPIAGLE vs OAGLE vs KOAGLE vs MAINAGLE vs NNNAGLE vs EPRTAGLE vs ADC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.